I read with interest the recently published story on the recommendations to streamline data collection in certain NCI trials presented at the Nov. 9, 2022, meeting of the Clinical and Translational Research Committee (The Cancer Letter, Nov. 11, 2022).
A “new normal” for NCI-sponsored clinical trials is long overdue
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Professor emeritus, University of Chicago; Former chief medical officer and executive vice president, American Society of Clinical Oncology; Former chair, Cancer and Leukemia Group B
Table of Contents
YOU MAY BE INTERESTED IN
Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.
Kate Choi grew up hearing conversations about skin cancer. Her grandparents had it, as did her cousins.
Cancer centers that continue to experience pandemic-induced shortages in staffing their clinical research enterprise may soon be able to rely on support from NCI’s Virtual Clinical Trials Office to open studies and accrue patients.
Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.
Edward Sondik, an electrical engineer by training, followed a career path that led him to top public health positions.He was a director of the National Center for Health Statistics at CDC, an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control.
